Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Har-Kcy
AddedMar 20, 2024
UpdatedJun 18, 2026
Har-Kcy

Har-Kcy

Seed

Innovative pharmaceutical company in Los Angeles, CA. Founded in 2015.

HQ
Los Angeles, CA, US
Founded
2015
Overview
Compare
Fundraising
Employees

Har-Kcy is an innovative pharmaceutical company based in Los Angeles, California, founded in 2015. The company focuses on developing cutting-edge medications and treatments to address unmet medical needs. Har-Kcy aims to improve patient outcomes through advanced research and development in pharmaceuticals.

Since its inception, Har-Kcy has achieved significant milestones in drug development and has made a notable impact in the pharmaceutical industry. The company's innovative approach has garnered attention from key stakeholders and investors, contributing to its growing influence in the market.

Har-Kcy - Similar Companies

Hyku logo

Hyku

Therio logo

Therio

Ikaria logo

Ikaria

Harmony Biosciences logo

Harmony Biosciences

Handa Pharmaceuticals logo

Handa Pharmaceuticals

handapharma.com

China PharmaHub logo

China PharmaHub

HighlightLL Pharma logo

HighlightLL Pharma

Turek Labs logo

Turek Labs

Dekkun logo

Dekkun

Kypha logo

Kypha

kypha.net

Compassionate Buds logo

Compassionate Buds

Essential Remedium logo

Essential Remedium

BiotechInnova logo

BiotechInnova

biotechinnova.com

Pctrx logo

Pctrx

Havix Group logo

Havix Group

Har-Kcy - Quick Facts

Who are Har-Kcy's competitors?

Companies similar to Har-Kcy include Hyku, Therio, Ikaria and Harmony Biosciences.

When was Har-Kcy founded?

Har-Kcy was founded in 2015.

Where is Har-Kcy's headquarters located?

Har-Kcy's headquarters is located in Los Angeles, CA, US.

When was Har-Kcy's last funding round?

Har-Kcy's most recent funding round was for $3M (USD) in December 2016.

How much has Har-Kcy raised to-date?

As of Dec 1, 2016, Har-Kcy has raised a total of $30M (USD).

How many employees does Har-Kcy have?

Har-Kcy has 5 employees as of Feb 5, 2024.

Har-Kcy - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Data
  • Software
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations